Welcome to our dedicated page for LENSAR news (Ticker: LNSR), a resource for investors and traders seeking the latest updates and insights on LENSAR stock.
LENSAR, Inc. (LNSR) is at the forefront of next-generation femtosecond laser technology, specializing in refractive cataract surgery. The company's flagship product, the LENSAR Laser System, offers unmatched precision and accuracy, optimizing visual outcomes for cataract patients. This cutting-edge system features the proprietary Augmented Reality™, LENSAR’s advanced 3-D imaging, measurement, and guidance technology. By providing high-resolution ocular images in a single scan, the system ensures precise surgical incisions and treatments, all within a single procedure room.
Unlike other femtosecond cataract lasers, the LENSAR Laser System is specifically built for refractive cataract surgery. Designed from the ground up with the needs of cataract surgeons in mind, the system integrates a suite of proprietary technologies aimed at improving visual outcomes, efficiency, and reproducibility. These technologies include Streamline IV and IntelliAxis, which assist surgeons with imaging, procedure planning, and precision.
At its core, LENSAR, Inc. is a commercial-stage medical device company committed to revolutionizing refractive eye surgery. Their product portfolio extends beyond the laser system to include the associated consumable components, such as the disposable patient interface device (PID) kits and procedure licenses necessary for each surgical procedure.
LENSAR's focus on innovation doesn't stop at technology. They are dedicated to building a vibrant team of talented and motivated individuals who share their passion for making a significant impact on patients' lives. The company continues to push the boundaries of what's possible in refractive cataract surgery, ensuring that their technology remains at the cutting edge of medical advancements.
LENSAR (Nasdaq: LNSR) has announced that its ALLY Adaptive Cataract Treatment System has received certification under the EU's Medical Device Regulation. This certification allows LENSAR to introduce ALLY to European surgeons, offering advanced laser technology for cataract procedures. ALLY is the first platform enabling seamless laser cataract procedures in a single, sterile environment.
Key features of ALLY include:
- Enhanced speed and ergonomic design for improved efficiency
- Artificial intelligence for iris registration and astigmatism management
- Automatic cataract density determination and optimization of fragmentation patterns
LENSAR (Nasdaq: LNSR) has granted stock options to three newly-hired non-executive employees as inducement awards. The options, totaling 1,925 shares of common stock, were approved by a majority of independent board members and issued on August 1, 2024. With an exercise price of $5.20 per share, matching the closing price on the grant date, these options have a 10-year term and a vesting schedule of 25% after one year, followed by 36 monthly installments. The grants, made under LENSAR's 2024 Employment Inducement Incentive Award Plan, comply with Nasdaq Listing Rule 5635(c)(4) and aim to attract new talent to the company.
LENSAR, Inc. (Nasdaq: LNSR), a global medical technology company specializing in advanced laser solutions for cataract treatment, has announced the release of its second quarter 2024 financial results. The results will be made public before the market opens on Thursday, August 8, 2024. Following this, LENSAR's management team will host a conference call and webcast at 8:30 am ET on the same day to discuss the financial outcomes and recent company highlights.
Interested parties can join the call by dialing (800) 274 8461 (Domestic) or (203) 518 9848 (International) using the conference ID: LENSAR. A live webcast will also be available in the Investors section of LENSAR's website at www.lensar.com. An archived version of the call will be accessible on the website after the live event.
LENSAR announced that its board of directors granted stock options to three new non-executive employees. A total of 1,200 shares are available for purchase under these options, which were issued as a hiring inducement. The grant date was July 2, 2024, and the exercise price is set at $4.31 per share, matching the closing stock price on that date. Options will vest 25% after one year from July 1, 2024, with the remaining shares vesting in equal monthly installments over the next three years, contingent on continued employment. Each stock option carries a 10-year term and follows LENSAR's 2024 Employment Inducement Incentive Award Plan.
LENSAR announced the inducement grants under Nasdaq Listing Rule 5635(c)(4), awarding stock options to three newly-hired non-executive employees. These options, totaling 2,150 shares, were granted as of June 3, 2024, with an exercise price of $4.64 per share, matching the closing price on the grant date. The vesting schedule includes 25% after one year and the remaining shares in equal monthly installments over the next three years. Each option has a 10-year term and is part of LENSAR's 2024 Employment Inducement Incentive Award Plan, subject to a stock option agreement.
LENSAR (Nasdaq: LNSR), a global leader in femtosecond laser solutions for cataract treatment, announced that CEO Nick Curtis will participate in a Fireside Chat at the 2024 Leerink Partners Healthcare Crossroads Conference. This event will take place on May 29, 2024, at 1:40 p.m. CT in Austin, TX.
The live and archived webcast will be accessible via the Investors section of LENSAR's website and will be available for one month after the presentation.
LENSAR, Inc. (Nasdaq: LNSR) reported a 28% increase in total revenue and a 25% increase in procedure volume for the first quarter of 2024 compared to the same period in 2023. The ALLY® Adaptive Cataract Treatment System installed base grew to 65 systems. The company achieved 20%+ revenue growth, with total revenue reaching $10.6 million, up 28% year-over-year. U.S. procedure volume increased by 23% and worldwide volume by 25% in Q1 2024. LENSAR's U.S. procedure share grew by 1.5% in Q1 2024 and has seen a 4.3% growth since the launch of ALLY.
LENSAR, Inc. (Nasdaq: LNSR) will report its first quarter 2024 financial results on Thursday, May 9, 2024. The global medical technology company specializing in femtosecond laser solutions for cataract treatment will host a conference call and webcast to discuss the results and recent corporate highlights.
LENSAR, Inc. (Nasdaq: LNSR) granted two newly-hired non-executive employees stock options to purchase 875 shares of common stock. The options were granted as of May 1, 2024, with an exercise price of $3.07 per share. They vest over time based on continued service. The options are in line with Nasdaq Listing Rule 5635(c)(4) and are subject to the company's 2024 Employment Inducement Incentive Award Plan.
FAQ
What is the current stock price of LENSAR (LNSR)?
What is the market cap of LENSAR (LNSR)?
What does LENSAR, Inc. specialize in?
What is the LENSAR Laser System?
What makes the LENSAR Laser System unique?
What is Augmented Reality™ in the context of LENSAR?
What is included in LENSAR's product portfolio?
What are the consumable components of the LENSAR Laser System?
What is the primary focus of LENSAR, Inc.?
How does LENSAR contribute to the surgical process?
How does LENSAR ensure the effectiveness of its technology?
What drives the success of LENSAR, Inc.?
